ARGX · CIK 0001697862 · FY2025 live · 2025-12-31
ARGENX SE
View as
Model
Classic Z
FY2025
3.23
Zone
Safe
Prior
—
Market DD
—
1y PD
—
3.23
Z″ 5.66
Score 3.23 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.001.2 × = 0.00X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
0.001.4 × = 0.00X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
0.003.3 × = 0.00X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
5.390.6 × = 3.23X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
85
0–100 · Classic Z family
Book standing
82
Year change
—
Market PD
—
O-score
93
Events on this name
Same published rows as Today.
Approaching grey
watch · 41
- Live score: — → 3.23
- Cut: — → 1.80
Overview
rule-v1
ARGENX SE is on classic Z at 3.23 (safe) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Safe; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 85th percentile in Healthcare.
- FDMTSafe4D Molecular Therapeutics, Inc.3.20
- ANIKSafeAnika Therapeutics, Inc.3.20
- TECHSafeBIO-TECHNE Corp3.20
- HRMYSafeHarmony Biosciences Holdings, Inc.3.32
- MAZESafeMaze Therapeutics, Inc.3.13
- UPCSafeUniverse Pharmaceuticals INC3.10
- NAMSSafeNewAmsterdam Pharma Co N.V.3.37
- AMLXSafeAmylyx Pharmaceuticals, Inc.3.09
Filing line items
Current assets
$0
Total assets
$8.7B
Current liabilities
$0
Total liabilities
$1.4B
Working capital
$0
Retained earnings
$0
EBIT
$0
Total sales
$0
Book equity
$7.3B
Accession 0001697862-26-000032. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.